A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.

被引：0
|
作者：
Gutierrez, Martin
Giaccone, Giuseppe
Harper, Harry D.
Liu, Stephen V.
Fang, Bruno
Ruiz, Jimmy
Hinson, James M.
Orlemans, Everardus Otto
Drilon, Alexander E.
机构：
[1] Hackensack Univ, Med Ctr, Reg Canc Care Associates, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Reg Canc Care Associates LLC, East Brunswick, NJ USA
[4] Wake Forest, Ctr Comprehens Canc, Winston Salem, NC USA
[5] Unicorn Pharma Consulting, Nashville, TN USA
[6] Esanex Inc, Indianapolis, IN USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19033
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [22] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers
    Harding, J.
    Hofheinz, R.
    Elez, E.
    Kuboki, Y.
    Geng, J.
    Schmohl, M.
    Dowling, E.
    Feng, Y.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S145 - S145
  • [23] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [24] Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
    Chen, Qiuyan
    Tang, Linquan
    Liu, Na
    Han, Feng
    Guo, Ling
    Guo, Shanshan
    Wang, Jianwei
    Liu, Huai
    Ye, Yanfang
    Zhang, Lu
    Liu, Liting
    Wang, Pan
    Li, Yingqin
    He, Qingmei
    Yang, Xiaoqun
    Tang, Qingnan
    Li, Yang
    Liang, YuJing
    Sun, XueSong
    Xie, Chuanmiao
    Mo, Yunxian
    Guo, Ying
    Sun, Rui
    Mo, Haoyuan
    Cao, Kajia
    Guo, Xiang
    Zeng, Musheng
    Mai, Haiqiang
    Ma, Jun
    CANCER COMMUNICATIONS, 2018, 38
  • [25] A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
    Doebele, R. C.
    Conkling, P.
    Traynor, A. M.
    Otterson, G. A.
    Zhao, Y.
    Wind, S.
    Stopfer, P.
    Kaiser, R.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2094 - 2102
  • [26] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [27] A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC
    Piha-Paul, Sarina
    Simon, George
    Belani, Chandra P.
    Chao, Heman
    Gaspar, Kim
    Lee, Brenda
    Dowlati, Afshin
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [28] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [29] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
  • [30] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
12345